Research Topics
Genomes and Genes | C OlanowSummaryAffiliation: Mount Sinai School of Medicine Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic studyFabrizio Stocchi
Institute of Neurology, IRCCS Neuromed, Pozzilli Is, Italy
Arch Neurol 62:905-10. 2005..Motor complications can be diminished with a continuous infusion of levodopa...- Rationale for considering that propargylamines might be neuroprotective in Parkinson's diseaseC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Neurology 66:S69-79. 2006..These results argue against the benefit being due to a symptomatic effect and are consistent with rasagiline having a protective effect... 
Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?C Warren Olanow
Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA
Mov Disord 28:31-40. 2013..We propose that this mechanism plays an important role in the development of PD and provides novel targets for candidate neuroprotective therapies. © 2013 Movement Disorder Society...- Tolcapone: an efficacy and safety review (2007)C Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York, NY 10029, USA
Clin Neuropharmacol 30:287-94. 2007..In addition, patients must be taken off the drug if blood tests show enzyme elevation of greater than twice the upper limit of normal. This article reviews the data pertaining to the safety and efficacy of tolcapone... - Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's diseaseC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Nat Clin Pract Neurol 2:382-92. 2006..The current challenge is to develop a long-acting oral formulation of levodopa that provides comparable anti-parkinsonian benefits without motor complications... - Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implicationsC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Lancet Neurol 5:677-87. 2006..The current challenge is to develop a long-acting oral formulation of levodopa that provides clinical benefits but avoids motor complications... - Movement disorders: a step in the right directionC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
Lancet Neurol 5:3-5. 2006 - Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategyC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 94, One Gustave L Levy Place, New York, NY 10029, USA
Mov Disord 20:S3-10. 2005..If implemented early in the course of the disease, such treatments, if found effective, may not only alter the natural progression of the disease but may also delay or minimize motor and nonmotor complications associated with levodopa... - Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson diseaseC W Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Arch Neurol 61:1563-8. 2004.... - Levodopa in the treatment of Parkinson's disease: current controversiesC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Mov Disord 19:997-1005. 2004..Clinical trials to test this hypothesis are underway. We review current evidence relating to these areas of controversy... - Lewy-body formation is an aggresome-related process: a hypothesisC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Lancet Neurol 3:496-503. 2004..The concept of Lewy bodies as aggresome-related inclusions fits well with ongoing discoveries suggesting that altered protein handling might contribute to the neurodegenerative process in familial and sporadic forms of PD... - Manganese-induced parkinsonism and Parkinson's diseaseC W Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
Ann N Y Acad Sci 1012:209-23. 2004..This is of particular relevance in differentiating patients with parkinsonism due to manganese intoxication from patients with idiopathic PD who have incidental manganese exposure... - Ubiquitin-proteasome system and Parkinson's diseaseC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, New York10029, USA
Mov Disord 21:1806-23. 2006..It also suggests novel targets for putative neuroprotective therapies for PD... - TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trialC Warren Olanow
Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
Lancet Neurol 5:1013-20. 2006..TCH346 is a potent anti-apoptotic drug that protects against loss of dopaminergic neurons in laboratory models. Our aim was to assess TCH346 as a neuroprotective drug in patients with Parkinson's disease... - Defining disease-modifying therapies for PD--a road map for moving forwardC Warren Olanow
Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York 10029, USA
Mov Disord 25:1774-9. 2010..Together these two trials provide a road map for defining a disease modifying drug and determining the long term cumulative effect of the drug on the disease... - Dopaminergic transplantation for Parkinson's disease: current status and future prospectsC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Ann Neurol 66:591-6. 2009..Collectively, these findings do not bode well for the short-term future of cell-based dopaminergic therapies in PD... - A double-blind, delayed-start trial of rasagiline in Parkinson's diseaseC Warren Olanow
Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
N Engl J Med 361:1268-78. 2009..A therapy that slows disease progression is the major unmet need in Parkinson's disease... - The scientific and clinical basis for the treatment of Parkinson disease (2009)C Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, 1 Gustave Levy Place, Annenberg 14 94, New York, NY 10029, USA
Neurology 72:S1-136. 2009..It is intended to provide physicians with an understanding of the different treatment options that are available for managing the different stages of the disease and the scientific rationale of the different approaches... - Can we achieve neuroprotection with currently available anti-parkinsonian interventions?C Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
Neurology 72:S59-64. 2009..This article reviews currently available drugs for PD and considers the evidence that they might have neuroprotective effects in PD... - Why have we failed to achieve neuroprotection in Parkinson's disease?C Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, USA
Ann Neurol 64:S101-10. 2008..New developments in understanding the cause of the disease, in the development of animal models of PD, and in clinical trial methodology will hopefully hasten the resolution of these problems... - A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristicsC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
Mov Disord 23:2194-201. 2008..We here describe the rationale for the study and baseline characteristics of the 1,176 patients who have been enrolled into the trial... - Levodopa/dopamine replacement strategies in Parkinson's disease--future directionsC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA
Mov Disord 23:S613-22. 2008..However, problems of continuous dopaminergic stimulation must be addressed and avoided, and the issue of nondopaminergic features remains to be addressed... - The pathogenesis of cell death in Parkinson's disease--2007C Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
Mov Disord 22:S335-42. 2007..It is anticipated that over the next few years there will be a flurry of scientific activity examining the mechanism of cell death and putative neuroprotective interventions... - The scientific basis for the current treatment of Parkinson's diseaseC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 94, One Gustave L Levy Place, Box 1137, New York, New York 10029, USA
Annu Rev Med 55:41-60. 2004..No drug has yet been established to alter the rate of disease progression, but the rapid pace of research offers reason for optimism... - Neuroprotection in Parkinson disease: mysteries, myths, and misconceptionsAnthony H V Schapira
University Department of Clinical Neurosciences, Royal Free and University College Medical School, and Institute of Neurology, Queen Square, London, England
JAMA 291:358-64. 2004..We review clinical trials aimed at detecting neuroprotection in Parkinson disease and address the controversies surrounding the interpretation of these studies... - Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysisC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
Mov Disord 24:336-43. 2009..Off-medication dyskinesias are common following transplantation and may represent a prolonged form of diphasic dyskinesias... - Surgical therapy for Parkinson's diseaseC W Olanow
Mount Sinai School of Medicine, Department of Neurology, New York, NY 10029, USA
Eur J Neurol 9:31-9. 2002..Stem cell, trophic factor, and gene therapy approaches are promising and are currently under intensive investigation... - Dietary vitamin E and Parkinson's disease: something to chew onC Warren Olanow
Department of Neurology, Box 1137, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
Lancet Neurol 2:74. 2003 - A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's diseaseC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
Ann Neurol 54:403-14. 2003..Fetal nigral transplantation currently cannot be recommended as a therapy for PD based on these results... - Proteasome inhibition causes nigral degeneration with inclusion bodies in ratsKevin St P McNaught
Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 73, One Gustave L Levy Place, New York, NY 10029, USA
Neuroreport 13:1437-41. 2002..These findings support the notion that failure of the ubiquitin-proteasome system to degrade and clear unwanted proteins is an important etiopathogenic factor in Parkinson's disease... - Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's diseaseKevin St P McNaught
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Ann Neurol 53:S73-84; discussion S84-6. 2003..It has also facilitated the development of experimental models that recapitulate the behavioral and pathological features of PD, and hopefully will lead to the development of novel neuroprotective therapies for the disorder... - Levodopa and the progression of Parkinson's diseaseStanley Fahn
Columbia University, New York, USA
N Engl J Med 351:2498-508. 2004..This study assessed the effect of levodopa on the rate of progression of Parkinson's disease... - COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?C Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10028, USA
Neurology 62:S72-81. 2004..This article considers the possibility that combining levodopa with entacapone may prevent or reverse motor complications... 
Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell linesVenugopalan D Nair
Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
Biochem J 373:25-32. 2003..These studies indicate that certain dopamine agonists can complex with D(2) receptors to preferentially transactivate neuroprotective signalling pathways and to mediate increased cell survival...- Early single cell bifurcation of pro- and antiapoptotic states during oxidative stressVenugopalan D Nair
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
J Biol Chem 279:27494-501. 2004..These studies suggest that the individual cell rapidly and stochastically processes the oxidative stress stimulus, leading to an all-or-none cytoprotective or pro-apoptotic signaling response... - Clinical usefulness of the Parkinson's disease sleep scaleWinona Tse
Department of Neurology, The Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
Parkinsonism Relat Disord 11:317-21. 2005..To test the usefulness of the Parkinson's disease sleep scale (PDSS) in identifying sleep disorders in the clinical practice setting... - Proteasomal dysfunction in sporadic Parkinson's diseaseKevin St P McNaught
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Neurology 66:S37-49. 2006..It remains to be established if proteasomal dysfunction plays a primary or a secondary role in the initiation or progression of the neurodegenerative process in PD... - Proteasome inhibitor-induced model of Parkinson's diseaseKevin St P McNaught
Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
Ann Neurol 60:243-7. 2006..We have begun to examine various factors that alone or in combination might explain these differences, and we present in this article preliminary results from these studies... - The neuropathology of manganese-induced ParkinsonismDaniel P Perl
Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
J Neuropathol Exp Neurol 66:675-82. 2007..These pathologic findings do not support the notion that manganese causes PD but rather argues that manganese-induced parkinsonism and PD are distinct and separate disease entities... - Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responsesVenugopalan D Nair
Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
J Biol Chem 283:15469-78. 2008..Inhibition of GSK-3beta activity by inhibitor VIII protects cells from H2O2 similar to ropinirole. These results indicate that GSK-3beta downstream of Akt plays a critical role in cell death and survival in these models... - Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stressCatherine Mytilineou
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
J Pharmacol Exp Ther 304:792-800. 2003..This study provides further evidence to support the notion that although levodopa can be toxic to dopamine neurons in vitro, it is not likely to be toxic to dopamine neurons in vivo and specifically in conditions such as PD... - p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibitionVenugopalan D Nair
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
J Biol Chem 281:39550-60. 2006..These results suggest that abnormalities in p53 signaling play a role in dopaminergic cell death induced by proteasome inhibition and may be relevant to neurodegeneration in PD... - Overexpression of torsinA in PC12 cells protects against toxicityP Shashidharan
Department of Neurology, Mount Sinai School of Medicine, New York 10029, USA
J Neurochem 88:1019-25. 2004..Overexpression of mutant torsinA failed to protect cells against trophic withdrawal. These results suggest that torsinA may play a protective role in neurons against a variety of cellular insults... - A model-based approach for assessing parkinsonian gait and effects of levodopa and deep brain stimulationCatherine Cho
Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
Conf Proc IEEE Eng Med Biol Soc 1:1228-31. 2006..In the present study, we determined whether model parameters were altered in subjects with PD when they were tested on/off levodopa (LD) and on/off deep brain stimulation (DBS) in a 2 x 2 matrix... - Prevalence of movement disorders in an elderly nursing home populationWinona Tse
Department of Neurology, Mount Sinai Medical Center, One Gustave L Levy Place, Box 1052, New York, NY 10029, USA
Arch Gerontol Geriatr 46:359-66. 2008..The discrepancy between our findings and the prevalence rates for parkinsonism reported on the initial transfer diagnosis emphasizes the difficulty of accurate diagnosis of movement disorders and in particular parkinsonism... - Aggresome-related biogenesis of Lewy bodiesKevin St P McNaught
Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 73, One Gustave L Levy Place, New York, NY 10029, USA
Eur J Neurosci 16:2136-48. 2002..This phenomenon is consistent with growing evidence that altered protein handling underlies the etiopathogenesis of PD and related disorders... - Protein aggregation in the pathogenesis of familial and sporadic Parkinson's diseaseKevin St P McNaught
Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 73, One Gustave L Levy Place, New York, NY 10029, USA
Neurobiol Aging 27:530-45. 2006..This suggests that manipulation of proteolytic systems is a rational approach in the development of neuroprotective therapies that could modify the pathological course of PD... - Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic culturesKevin St P McNaught
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
J Neurochem 81:301-6. 2002..This study supports the concept that defects in the UPS may underlie nigral pathology in familial and sporadic forms of PD... - Frequency-velocity mismatch: a fundamental abnormality in parkinsonian gaitCatherine Cho
Department of Neurology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, Box 1135, New York, NY 10029 6574, USA
J Neurophysiol 103:1478-89. 2010..We postulate that the inability to control step frequency and adjust swing phase dynamics to slower walking velocities are major causes for the gait impairment in PD... - Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's diseaseKevin St P McNaught
Department of Neurology, Neuropathology Division, Mount Sinai School of Medicine, New York, NY 10029, USA
Ann Neurol 56:149-62. 2004..This animal model induced by proteasome inhibitors closely recapitulates key features of PD and may be valuable in studying etiopathogenic mechanisms and putative neuroprotective therapies for the illness... - Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's diseaseKevin St P McNaught
Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 73, One Gustave L Levy Place, New York, NY 10029, USA
Neurosci Lett 326:155-8. 2002..Thus, structural and function defects in 26/20S proteasomes may underlie protein accumulation, formation of proteinaceous Lewy bodies and dopaminergic neuronal death in the SNc in sporadic PD... - Brainstem pathology in DYT1 primary torsion dystoniaKevin St P McNaught
Department of Neurology, Neuropathology Division, Mount Sinai School of Medicine, New York, NY 10029, USA
Ann Neurol 56:540-7. 2004..and cuneiform nuclei, and related brainstem brainstem structures, in mediating motor activity and controlling muscle tone suggests that alterations in these structures could underlie the pathophysiology of DYT1 dystonia [corrected].. - Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)C Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA
Clin Neuropharmacol 27:58-62. 2004 - Unilateral stimulation of the subthalamic nucleus in Parkinson disease: a double-blind 12-month evaluation studyIsabelle M Germano
Department of Neurosurgery, The Mount Sinai School of Medicine, New York, New York 10029 6574, USA
J Neurosurg 101:36-42. 2004..Nevertheless, bilateral surgical procedures can be associated with frequent and severe complications. The aim in the present study was to assess the safety and efficacy of unilateral STN stimulation, and the need for a second procedure... - Present and future directions in the management of motor complications in patients with advanced PDC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
Neurology 61:S24-33. 2003 - The role of dopamine agonists in the treatment of early Parkinson's diseaseC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Neurology 58:S33-41. 2002.... - Neuroprotective agents in Parkinson's disease: clinical evidence and caveatsThomas D Hälbig
Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
Neurol Clin 22:S1-S17. 2004 - Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trialWilliam J Marks
Department of Neurology, University of California San Francisco, San Francisco, CA, USA
Lancet Neurol 9:1164-72. 2010..We aimed to assess the safety and efficacy of AAV2-neurturin in a double-blind, phase 2 randomised trial... - Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutantsXianting Li
Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, USA
J Neurochem 103:238-47. 2007..The distinctive levels of kinase/GTPase activity in brain LRRK2 may help explain LRRK2-associated neuronal functions or dysfunctions in the pathogenesis of PD... - Sleepiness in Parkinson's disease: a controlled studyMatthew A Brodsky
Mount Sinai School of Medicine, New York, New York 10029, USA
Mov Disord 18:668-72. 2003..These findings support the notion that sleep episodes while driving in PD patients are related to excess daytime sleepiness and dopaminergic load. Physicians should advise and treat patients accordingly... - Stem cell treatment for Parkinson's disease: an update for 2005Brian J Snyder
Department of Neurosurgery, Mount Sinai School of Medicine, New York, NY 10029, USA
Curr Opin Neurol 18:376-85. 2005.... - Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolitesBrian C Kramer
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Eur J Neurosci 19:280-6. 2004..Our study suggests that limiting AA release and metabolism may provide benefit in conditions with an existing depletion of GSH, such as Parkinson's disease... - Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's diseaseAnthony H V Schapira
University Department of Clinical Neurosciences, Royal Free and University College Medical School, UCL, Queen Square, London, United Kingdom
Ann Neurol 53:S149-57; discussion S157-9. 2003 - Movement disorders and AIDS: a reviewWinona Tse
Department of Neurology, Mount Sinai Medical Center, One Gustave L Levy Place, Box 1052, New York, NY 10029, USA
Parkinsonism Relat Disord 10:323-34. 2004..This review will also summarize current concepts regarding the pathophysiology of parkinsonism in HIV infection... - Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trialWilliam J Marks
Department of Neurology, University of California, San Francisco, San Francisco, CA 94143 0138, USA
Lancet Neurol 7:400-8. 2008..The aim of this study was to assess the safety, tolerability, and potential efficacy of gene delivery of the neurotrophic factor neurturin... - Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trialIra Shoulson
University of Rochester Medical Center, Rochester, NY 14620, USA
Ann Neurol 51:604-12. 2002.... - Continuous dopaminergic stimulation in early and advanced Parkinson's diseaseFabrizio Stocchi
Department of Neuroscience and IRCCS Neuromed Pozzilli (IS, University La Sapienza, Rome, Italy
Neurology 62:S56-63. 2004..Therefore, the development of a simple treatment regimen using an oral formulation of levodopa to provide a more continuous dopaminergic stimulation will represent a significant advance in antiparkinsonian pharmacotherapy... - Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patientsMatthew B Stern
University of Pennsylvania, Philadelphia, Pennsylvania, USA
Mov Disord 19:916-23. 2004..05, Fisher's exact test). The frequency and types of adverse events reported by rasagiline-treated and placebo-treated patients were similar. These results suggest that rasagiline monotherapy is well tolerated and efficacious in early PD... - Progress in clinical neurosciences: a forum on the early management of Parkinson's diseaseAnthony E Lang
Division of Neurology, Department of Medicine, University of Toronto, Toronto Western Hospital, Canada
Can J Neurol Sci 32:277-86. 2005..This report summarizes presentations and discussion dealing with these issues from a one-day symposium involving Canadian Movement Disorders neurologists... - Double-blind, placebo-controlled trials for surgical interventions in Parkinson diseaseC Warren Olanow
Arch Neurol 62:1343-4. 2005 - The pathogenesis of cell death in Parkinson's diseasePeter Jenner
Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King s College, London, United Kingdom
Neurology 66:S24-36. 2006..This is an essential step to understanding pathogenesis and is critical to the development of comprehensive neuroprotective approaches to treatment... - Altered proteasomal function in sporadic Parkinson's diseaseKevin St P McNaught
Neurodegenerative Disease Research Centre, GKT School of Biomedical Sciences, King's College, London Bridge, London SE1 1UL, UK
Exp Neurol 179:38-46. 2003..These findings suggest that failure of the ubiquitin-proteasome system to adequately clear unwanted proteins may underlie vulnerability and degeneration of the SNc in both sporadic and familial PD... - Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's diseaseJeffrey H Kordower
Department of Neurological Sciences and Center for Brain Repair, Rush University Medical Center, 1735 West Harrison Street, Chicago, Illinois 60612, USA
Nat Med 14:504-6. 2008..These findings have implications for cell-based therapies and for understanding the cause of Parkinson's disease... - Neuroprotection in Parkinson's disease: clinical trialsFabrizio Stocchi
Department of Neuroscience and Neuromed, University La Sapienza, Rome, Italy
Ann Neurol 53:S87-97; discussion S97-9. 2003..Currently, this will most likely entail demonstrating that the drug provides benefit for PD patients for both imaging and clinical markers of disease progression... - Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trialChristopher G Goetz
Rush University Medical Center, Chicago, Illinois 60612, USA
Mov Disord 22:179-86. 2007..Sarizotan 2 mg/day is a safe agent in PD patients with dyskinesia. To test its role in abating dyskinesia, future studies should focus on this dose and will use the composite score of UPDRS Items 32+33 as the primary outcome... - Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trialConnie Marras
Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
Mov Disord 23:653-9; quiz 776. 2008..Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL... - Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing planChristopher G Goetz
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
Mov Disord 22:41-7. 2007.... - Neuroprotection for Parkinson's disease: prospects and promisesC Warren Olanow
Ann Neurol 53:S1-2. 2003 - Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's diseaseFabrizio Stocchi
Institute of Neurology and Neuromed, University La Sapienza, Viale dell Universita 30, 00185 Rome, Italy
Brain 125:2058-66. 2002..This study indicates that continuous lisuride infusion can be beneficial for patients with advanced Parkinson's disease and reverse established motor fluctuations and dyskinesia...
Research Grants
- DOUBLE-BLIND CONTROLLED TRIAL OF NIGRAL GRAFTING IN PDC Olanow; Fiscal Year: 2003..abstract_text> ..